The report offers new insights into the limits of the BCL2 inhibitor among patients who have myelodysplastic syndromes. A new report explains why patients with myelodysplastic syndromes (MDS) become ...
Shorter-duration venetoclax may be as effective as longer-duration treatment in AML and MDS, with no significant impact on overall survival. The study included 53 patients, predominantly male, with a ...
Nutrition may improve quality of life and outcomes in people with myelodysplastic syndromes (MDS). Myelodysplastic syndromes (MDS) are a type of blood cancer. Typically, blood stem cells mature into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results